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Abstract The signal transduction pathways involving phospho-
lipid metabolism during T-cell proliferation remain partly
undefined. Herein we show that interleukin-2 caused a late
(s 12 h) rise in the intracellular phosphatidic acid content of
CTLL-2 cells which was a consequence of the activation of the
enzyme diacylglycerol kinase. No activation of phospholipase D
was observed at similar times. Incubation of the cells with a
recognized diacylglycerol kinase K isoform inhibitor, R59499,
prior to interleukin-2 stimulation was able to block cell cycle
entry, diacyglycerol kinase activation and phosphatidic acid
accumulation. In contrast, when R59499 was added 3 h after
interleukin-2, few or no observable effects on the above three
parameters were noticed. These results suggest that the early
signaling employed by IL-2 involving the K isoform of
diacylglycerol kinase is sufficient to control the late increase in
phosphatidic acid and that phosphatidic acid is a mitogenic agent
in T-cells.
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1. Introduction
Interleukin-2 (IL-2) is a cytokine which is responsible for
the expansion of T-cell populations. Although it was discov-
ered over two decades ago, its signal transduction pathways
are still not fully de¢ned. After ligation to its high a⁄nity
heterotrimeric receptor, transmembrane signaling cascades
are generated within seconds. A large number of the signals
have been partially characterized with the involvement of both
protein and lipid kinases [1^8] which associate with the indi-
vidual chains of the IL-2 receptor at speci¢c sites. These sig-
nals integrate with each other to stimulate protooncogene
production and to control the activity of the cell cycle protein
machinery [9]. Activation of multiple pathways leads to en-
hanced protein phosphorylation, however the role of phos-
pholipids and in particular phospholipid-derived second mes-
sengers remains understudied and unclear. It has been
demonstrated that IL-2 does not show characteristics of an
agent which delivers a classical transmembrane signal in that
phosphatidylinositol turnover, calcium £uxes and cyclic nu-
cleotide generation are not observed [10^12]. Two lines of
evidence have emerged in an attempt to understand the role
of lipid second messengers for IL-2. Firstly, IL-2 causes the
rapid phospholipase C-mediated hydrolysis of glycosylphos-
phatidylinositol [13,14] and secondly, diacylglycerol (DAG)
kinase (DGK) activity is increased [15,16]. Phosphatidic acid
(PA) is considered, as is DAG, to be a mitogenic agent as it is
able to activate a number of enzymes and to regulate intra-
cellular metabolism [17]. PA arises not only through the ac-
tivity of DGK, but also via the action of phospholipase D
(PLD) which generates PA directly [18,19]. On examining the
kinetics of the generation of lipid second messengers after
extracellular stimulation, it becomes apparent that in addition
to the ‘early and transient phospholipid signaling’, attribut-
able principally to the hydrolysis of polyphosphoinositides,
there exists a second wave of phospholipid hydrolysis whose
duration is greater than that observed at short times after
receptor stimulation. This second wave of phospholipid hy-
drolysis which increases the intracellular concentration of lip-
id second messengers, including DAG and PA, gives rise to
the sustained activation of protein kinases thereby driving the
cells into mitogenesis and/or di¡erentiation [18^20]. The vast
majority of investigators who have examined the IL-2-induced
signal transduction have done so using short periods of stim-
ulation and have based their conclusions on such experiments.
In the light of the very recent observation that IL-2 causes a
sustained increase in the level of intracellular DAG in CTLL-
2 cells [21], we have re-examined the ‘late phase’ of IL-2 signal
transduction and demonstrate a strong stimulation of DGK
which is responsible for rises in intracellular PA.
2. Materials and methods
2.1. Materials
Human recombinant IL-2 was a generous gift from Ho¡man-
LaRoche Inc. (Nutley, NJ, USA). [32P]Orthophosphate (carrier free)
and [Q-32P]ATP (speci¢c activity 3000 Ci/mmol) were purchased from
Amersham (Amersham, UK). Fetal calf and newborn calf sera were
bought from Gibco (Paisley, UK) and Bio Whittaker (Walkersville,
MD, USA) respectively. Silica gel TLC plates (60 Aî , LK6D) were
from Whatman (Clifton, NJ, USA). R59949 was purchased from
Calbiochem (Nottingham, UK). Authentic phospholipid standards
for TLC, 1,2-dioleoyl-sn-glycerol, phorbol ester (PMA) and cabbage
PLD were from Sigma (Poole, UK). Phosphatidylethanol (PEt) was
from Avanti Polar Lipids (Alabaster, AL, USA).
2.2. Cell culture and cell cycle analysis
CTLL-2 (clone G7) cells were maintained according to Flores et al.
[16]. KIT225 cells were cultured likewise. NIH3T3 cells were grown in
petri dishes in DMEM containing 10% v/v newborn calf serum, 2 mM
glutamine, 100 U/ml penicillin, 100 Wg/ml streptomycin bu¡ered to pH
7.2 with 10 mM HEPES. All cell types were passaged twice weekly
before they became con£uent. Cell cycle analyses were performed as
previously described [16].
2.3. Non-radioactive cell treatments
CTLL-2 cells were washed twice in incomplete medium (RPMI
supplemented with 2 mM glutamine, 50 WM 2-mercaptoethanol, 100
U/ml penicillin, 100 Wg/ml streptomycin bu¡ered to pH 7.2 with 10
mM HEPES) before reincubating during a starving period of 8 h. At
this point cell treatments were initiated. Cells were incubated at a
density of 5U105/ml in the absence or presence of 50 U/ml IL-2 for
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various times after which the cells were pelleted, washed twice using
ice-cold PBS and stored at 380‡C. In the case of experiments using
the DGK inhibitor, R59949, cells were either pre-incubated (30 min)
with the compound before stimulation with IL-2 or the compound
was added 3 h after IL-2. In all cases R59949 was used at 1 WM
without observable toxic e¡ects.
2.4. In vivo metabolic labeling
CTLL-2 cells were prepared as above and metabolically labeled to
equilibrium during the starvation period using orthophosphate (50
WCi/ml) in phosphate-free incomplete medium followed by treatment
with or without R59949 and IL-2 as indicated above. At the end of
the incubations, cells were pelleted, washed twice in ice-cold PBS and
stored at 320‡C. Additionally, in some experiments 1% (v/v) ethanol
was included in the cell incubations during the last 30 min of the IL-2
stimulation period. NIH3T3 cells (grown in six-well plates), KIT225
and CTLL-2 cells were metabolically labeled as indicated above. After
stimulation with combinations of ethanol, IL-2 and PMA (100 nM)
during a period of 30 min, the cells were rapidly washed with ice-cold
PBS, collected by centrifugation or trypsinization and stored at
320‡C.
2.5. Biochemical and enzymatic assays
DGK activity was determined using the method described by Flores
et al. [16]. Phospholipids were extracted by the method of Bligh and
Dyer [22] and subjected to TLC using a solvent system consisting of
chloroform/methanol/glacial acetic acid (9:1:1, v/v/v) for the separa-
tion of labeled PA. After drying, the TLC plates were exposed to ¢lm
and the bands corresponding to labeled PA (found by comigration
with an authentic PA marker) were quanti¢ed using phosphorimaging
analysis (Molecular Analyst Software, Bio-Rad). Accumulation of PA
in cells after metabolic labeling of CTLL-2 cells was determined by
phospholipid extraction of the cell pellets followed by TLC employing
the same mobile phase. Autoradiography and quanti¢cation of radio-
active spots corresponding to PA were performed as described above.
The formation of PEt (a recognized marker of PLD activity) in meta-
bolically labeled cells was determined by phospholipid extraction of
the cell pellets followed by TLC employing the solvent system chloro-
form/methanol/glacial acetic acid (65:15:2, v/v/v) with authentic PEt
as the TLC standard. PLD activity was also assessed in a crude
membrane fraction using a £uorescent assay previously described
[23]. As a positive control the £uorescent substrate (phosphatidylcho-
line) was incubated with 25 U of cabbage PLD in the presence or
absence of butanol. Fluorescent phospholipids were extracted by the
method of Bligh and Dyer [22] and subjected to TLC using a solvent
system consisting of chloroform/methanol/glacial acetic acid (65:15:2,
v/v/v). After drying, the TLC plates were illuminated with ultraviolet
light and photographed. Fluorescent PA and £uorescent phosphati-
dylbutanol were used as marker phospholipids. The method of Bart-
lett [24] was used for the assay of total phosphate.
3. Results
Our ¢rst objective was to measure long-term variations in
the level of PA in CTLL-2 cells treated with IL-2. Therefore
we decided to use orthophosphate radiolabeling as we found
that it was readily incorporated into PA and furthermore it
would enable us to determine total PA generation. Fig. 1
shows that there was an accumulation of PA in CTLL-2 cells
that had been stimulated with IL-2. This accumulation was
apparent at 12 h (approximately 3-fold over control) and was
sustained until at least 24 h (increasing to approximately 4-
fold over control).
As it has been described in other systems that a late sus-
tained accumulation of PA may arise from the action of PLD
on phosphatidylcholine [18,19], we decided to determine if IL-
2 stimulated PLD at late times after CTLL-2 cell stimulation.
We used two techniques. The ¢rst involved in vivo metabolic
radiolabeling whereas the second method involved an in vitro
PLD assay using a £uorescent substrate. At all the times in-
dicated above no activation of PLD was detected in IL-2-
stimulated cells (data not shown). To determine if PLD was
activated by IL-2 at short time periods (up to 30 min), both
PLD assay techniques were employed. Neither IL-2 nor PMA
was able to stimulate PLD activity in metabolically radiola-
beled CTLL-2 cells (Fig. 2). To con¢rm this negative result
with a positive control, KIT225 and NIH3T3 cells, which had
been subjected to the same metabolic radiolabeling procedure
as CTLL-2 cells, were stimulated with PMA. A large increase
in PLD activity in both cells types was observed after treat-
ment with PMA (Fig. 2).
As the observed IL-2-dependent increase in intracellular PA
was not due to stimulated PLD activity, we determined DGK
activity in membrane extracts of CTLL-2 cells that had been
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Fig. 1. IL-2 causes a late sustained accumulation of PA. CTLL-2
cells were radiolabeled/arrested and then incubated for various times
with or without IL-2. Radiolabeled cellular PA levels were normal-
ized to total phospholipid phosphate (phosphorimaging analysis pix-
el density of PA/nmol phospholipid phosphate). This ¢gure depicts
the combined results of three independent experiments (mean þ
S.D.).
Fig. 2. IL-2 does not acutely stimulate PLD. CTLL-2 (A), NIH3T3
(B) and KIT225 (C) cells were radiolabeled with orthophosphate in
phosphate-free medium in the absence of serum and growth factors.
Thereafter cells were control treated or treated with ethanol in the
presence or absence of IL-2 or PMA for 30 min. After phospholipid
extraction, radiolabeled PEt was separated from all other phospho-
lipids by TLC. The results are representative of two further inde-
pendent experiments.
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treated with IL-2. DGK was clearly activated (approximately
2^3-fold over control) and remained so up to at least 24 h
after stimulation (Fig. 3).
DGK enzymes exist as a family of at least eight isoforms
whose di¡erences are accounted for within their structure and
their sites of expression [25]. Previous work from our labora-
tory has indicated that IL-2 raises PA levels at early time
points after receptor ligation through the speci¢c activation
of the K isoform of DGK [16]. The compound R59949 has
been shown to be an inhibitor of the K isoform of DGK
[25,26]. To investigate if the DGK activity stimulated at later
times following IL-2 addition corresponded to the activation
of the K isoform we decided to test the e¡ect of R59949
addition either before or after IL-2 stimulation. CTLL-2 cells
were either pre-incubated with R59949 before IL-2 stimula-
tion or were treated with the inhibitor 3 h after IL-2 stimu-
lation. As we have previously described [16], pre-incubation of
the cells with R59949 before IL-2 stimulation prevented cell
cycle entry and led to a build up of cells in G0/G1. In contrast,
Fig. 4A indicates that those cells which received IL-2 stimu-
lation followed by treatment with R59949 entered into the cell
cycle almost identically to those stimulated by IL-2. The pro-
portion of cells committed to DNA synthesis and mitosis in
both cases was approximately 3-fold over that observed in
unstimulated cells. As pre-treatment, but not post-treatment,
of CTLL-2 cells with R59949 was able to prevent IL-2-medi-
ated cell proliferation, we decided to determine the e¡ect of
R59949 on PA generation and DGK activation. Fig. 4B in-
dicates that cells that had been treated with R59949 before
stimulation with IL-2 failed to increase their PA levels above
non-stimulated cells, whereas those cells that had been stimu-
lated with IL-2 3 h before treatment with R59949 accumu-
lated PA to a similar extent to cells which had only been
stimulated with IL-2. In addition, the e¡ect of R59949 on
long-term IL-2-stimulated DGK activity was investigated. In
accordance with the observations that both cell proliferation
and PA accumulation at 18 and 24 h in cells stimulated with
IL-2 were identical to those in cells treated with R59949 3 h
after IL-2 stimulation, no di¡erences in DGK activity in
membrane extracts from identically treated CTLL-2 cells
were observed (Fig. 5).
4. Discussion
There are several reports in the literature describing that IL-
2 does not activate classical mechanisms but instead it pro-
vokes the rapid activation of novel phospholipid metabolism
[7,8,10^16]. All these events take place within seconds to min-
utes after the union of IL-2 with its receptor. The rationale
behind our study was to investigate the long-term e¡ects of
IL-2 on lipid second messenger generation and to ¢ll in the
gap in the understanding of the late phase of IL-2 action.
Without doubt the roles of lipid second messengers have
been extensively studied in several cell types [27]. In the case
of lymphocytes, this aspect of cell signaling has been scarcely
examined and to the present date there are no data with
respect to IL-2-induced long-term increases in PA. With the
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Fig. 4. E¡ect of the DGKK inhibitor R59949 on IL-2-stimulated
cell proliferation and PA accumulation. A: CTLL-2 cells were ar-
rested and then incubated for various times with or without IL-2.
R59949 was added to the cells 30 min before or 3 h after IL-2 stim-
ulation. Cell cycle analyses were performed 18 and 24 h after IL-2
stimulation. The percentage distribution of cells within regions of
the cell cycle pro¢le is indicated for each cell treatment. Shown here
are the results from one experiment representative of two experi-
ments with similar results. B: CTLL-2 cells were arrested, radiola-
beled (according to the legend of Fig. 1) and treated as indicated
above with combinations of IL-2 and R59949. Intracellular PA was
determined at 18 and 24 h after IL-2 stimulation according to the
legend of Fig. 1. This ¢gure depicts the combined results of two in-
dependent experiments (mean þ S.D.).
Fig. 3. IL-2 causes a late sustained activation of DGK. CTLL-2
cells were arrested and then incubated for various times with or
without IL-2. DGK activity was determined in crude membrane ex-
tracts. Shown here is the digitized image of a TLC plate corre-
sponding to the region of PA (A) and its quanti¢cation by phos-
phorimaging (B) which is representative of three experiments with
similar results.
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recent observation that IL-2 causes a delayed and sustained
increase in the level of DAG in CTLL-2 cells, which correlates
with the induction of S-phase entry, [21] and that numerous
growth factors cause the long-term elevation of DAG levels
[18^20], we decided to investigate the possibility that in addi-
tion to DAG, PA accumulated in the cells as a consequence of
IL-2 stimulation. Our results demonstrate that this was indeed
the case as a late and sustained increase in PA was observed.
PLD is the unique phospholipase which, when in the pres-
ence of a primary aliphatic alcohol, such as ethanol, may
catalyze a transphosphatidylation reaction in which the phos-
phatidyl moiety is transferred to an alcohol molecule forming
a phosphatidylalcohol (for example PEt). This reaction is con-
sidered to be unequivocal evidence for PLD activity [18,19]. In
both highly metabolically labeled cells and cell extracts, no
PLD activity was observed at the times when the late IL-2-
stimulated PA accumulation occurred. In addition, no acute
IL-2 stimulation of PLD in CTLL-2 cells was observed which
was in disagreement with the observations by Cano and co-
workers [28]. Using NIH3T3 ¢broblasts as a positive control,
PMA, the activator of classical isoforms of PKC, was able to
increase PLD activity. This e¡ect was not observed in CTLL-
2 cells. As there was no activation of PLD using IL-2 or
PMA, it was considered that PLD was not expressed in
CTLL-2 cells. Unfortunately, no antibodies are currently
available to examine the expression of any of the PLD iso-
forms so far known. Our lack of PMA-responsive PLD activ-
ity in murine CTLL-2 cells in contrast to PMA-responsive
PLD activity in human KIT225 cells is supported in part by
the ¢nding that in the murine EL4 T-lymphocyte cell line no
activation of PLD by PMA is observed [29] whereas in human
Jurkat cells PLD activation by PMA and TCR antibody cross
linking is seen [29,30], suggesting that, in lymphocytes, PLD
activation does take place but its speci¢city depends on the
ligand and/or the origin of the lymphocytes used.
As PLD activity was not stimulated by IL-2, the other route
by which IL-2 could have generated PA was through the
activation of DGK. Our results demonstrate a late and sus-
tained increase in PA that mirrored the stimulation of DGK
activity. The exact role of elevated PA levels in CTLL-2 cells
is unknown, but as PA is considered to be a mitogenic agent
in many cell types [17^19] similar mitogenic activity may be
important in CTLL-2 cells. This late activation of DGK by
IL-2 shows some similarity to that seen in other cell types
[31,32]. With the clear correlation between the time course
of DGK activation and PA accumulation induced by IL-2,
it was concluded that this elevated activity was totally respon-
sible for the IL-2-stimulated accumulation of PA.
Flores and co-workers have demonstrated that IL-2 delivers
its mitogenic signal in part through the K isoform of DGK
[16] which is an isoform both sensitive to R59949 and highly
expressed in T-cells [33]. Herein we have built on this ¢nding
by investigating if by pharmacological modulation of the early
activation of DGKK, the subsequent second wave of PA ac-
cumulation is a¡ected. This was indeed the case. However,
this was not observed when the R59949 was added to the cells
3 h after IL-2. This would implicate that the ‘early signaling’
involving DGKK, i.e. that occurring within 3 h of IL-2 stim-
ulation, is able to positively regulate PA production at 10 or
more hours later. No inhibition following post 3 h treatment
of IL-2-stimulated cells with R59949 rules out that the KDGK
isoform is responsible for the long-term generation of PA. The
DGK assays performed herein used a crude membrane frac-
tion as antibodies against murine isoforms of DGK still re-
main unavailable. Therefore it was di⁄cult to identify which
of the known DGK isoenzymes could have been activated at
late time periods by IL-2. In addition, the possibility of as yet
undiscovered novel isoforms of DGK participating during late
IL-2-mediated phospholipid metabolism cannot be excluded.
Experiments are under way to identify DGK isoforms which
are responsible for the late IL-2-stimulated generation of PA.
In summary, this paper has demonstrated for the ¢rst time
that in CTLL-2 cells IL-2 causes the late generation of not
only DAG but also PA. This observation shows general sim-
ilarity to that seen in other transmembrane signaling systems
but the pathways for their generation in CTLL-2 cells by IL-2
are substantially di¡erent. The lipid second messengers termed
DAG and PA are in reality only generic names for the many
subtypes, due to the multiplicity of fatty acids and their cor-
responding acyl and/or alkyl linkages to glycerol, found with-
in these lipid fractions [27]. This is becoming an important
feature of agonist-stimulated signal transduction in that the
identi¢cation of individual species of DAG and PA that con-
fer microspeci¢city on the activation and/or inhibition of spe-
ci¢c enzymes are the targets for the future design of valid
drugs to combat various immunological diseases and undesir-
able states.
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Fig. 5. E¡ect of the DGKK inhibitor R59949 on IL-2-stimulated
DGK activity. After arresting CTLL-2 cells, half were stimulated
with IL-2 whereas the other half received identical IL-2 stimulation
followed 3 h later by treatment with R59949. DGK activity was de-
termined in crude membrane extracts after 18 and 24 h of IL-2
stimulation. Shown here is the digitized image of a TLC plate corre-
sponding to the region of PA (A) and its quanti¢cation by phos-
phorimaging (B) which is representative of two experiments with
similar results.
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